Brookline Capital Markets Starts Progenics Pharmaceuticals (PGNX) at Buy Citing Favorable Risk/Reward
Tweet Send to a Friend
Brookline Capital Markets initiates coverage on Progenics Pharmaceuticals (NASDAQ: PGNX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
